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ARTICLE INFO                                         ABSTRACT
 
 
Background: 
impairments. The progression of reversible cognitive disorders can be halted by identifying and 
treating the underlying cause. 
Aim of the Review: 
impairment and investigate the possibility of pharmacist involvement in the identification of and/or 
protection against cognitive impairment.
Method: 
language of 1975
Results: 
cognitive impairment.
impairment caused by medications.
Conclusion: 
medications through appropriate management of the underlying problem. This may contribute to 
patients’ better health outcomes and quality of life.
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INTRODUCTION  
 
The human brain changes physiologically with aging 
Endo, 2010). The aging process results in a profound impact 
on multiple levels ranging from sub-cellular to macro
structural changes (Sato and Endo, 2010
conditions can damage various biological and physiological 
systems which directly or indirectly maintain optimal brain 
function and result in physical deterioration of the brain and 
subsequent cognitive decline. Some of these conditions are 
irreversible such as traumatic brain injuries, stroke
dementia. However, there are other factors which can lead to 
reversible or modifiable cognitive impairment. The 
progression of reversible cognitive disorders can be halted by 
identifying and treating the underlying cause of the symptoms. 
With appropriate treatment, a person's previous level of 
functioning can be restored or improved if the cause is not 
organ damage. Thus, cognitive impairment is often classified
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There are various factors which can lead to irreversible, reversible cognitive 
 
To expand pharmacists’ knowledge on underlying causes of cognitive 
 
A search of the literature was conducted through databases to identify studies in the English 
-2016. Peer-reviewed articles and informational websites were included.
There are two broad classifications of cognitive impairment, irreversible and reversible 
 Pharmacists can play an essential role in 
 
Pharmacists have the potential to lead early detection of cogniti
 
access article distributed under the Creative Commons Attribution 
the original work is properly cited. 
(Sato and 
-
). Also, medical 
 and 
 
. 
 
 
into two broad categories; irreversible (not curable) and 
reversible (curable) based on the cause.
 
Aim of the review 
 
The aim of this review is to expand pharmacists’ knowledge on 
underlying causes of cognitive impairment and investigate the 
possibility of pharmacist involvement in identification of 
and/or protection against cognitive impairment.
 
MATERIALS AND METHODS
 
A search of the literature was conducted through Medline™, 
Embase™ and Google™ Scholar databases to identify studies 
in English language between 1975 and
keywords were used: cognitive impairment, cognitive 
impairment AND causes, cognitive impairment AND 
modifiable causes, cognitive impairment AND non
causes, cognitive impairment AND medications and 
pharmacist role AND cogniti
commentaries and commercial websites were excluded, only 
peer reviewed articles and informational websites were 
included. (Table I) 
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RESULTS  
 
Non-modifiable causes (irreversible) of cognitive 
impairment 
 
While it is not included under the aim of this paper, it is 
mentioned here to clarify the difference between the two 
pathways of cognitive compromise causes and to demonstrate 
that most of the current literature is concentrating on these 
when compared to modifiable causes. 
 
Aging 
 
Neuronal and mitochondrial membranes deteriorate with aging 
which results in impaired neuronal function and loss of cellular 
integrity (Sato and Endo, 2010). Additionally, with aging, 
neurotransmitter synthesis and signalling declines (Backman, 
Lindenberger, Li, and Nyberg, 2010) coupled with reductions 
in synaptic adaptability and density (Sametsky, Disterhoft, 
Geinisman, and Nicholson, 2010)and a loss in the length of 
myelinated axons of as much as fifty percent (Backman et al., 
2010).  Furthermore, with age, the physical structure of the 
brain deteriorates as a whole (Fjell and Walhovd, 2010). The 
sub-cortical volume in some regions of the brain and the 
cortical thickness reduces annually as much as 0.5% to 1.0% 
due to the reduced functional synapses and synaptic spine 
numbers, and the death and shrinkage of neurons (Fjell and 
Walhovd, 2010). Thus, age-related physical degradation of 
brain structure results in cognitive decline (Fjell and Walhovd, 
2010). It has been estimated that the age related 
neuroanatomical changes account for between 25% and 100% 
of the variance in cognitive ability between young and aged 
individuals (Fjell and Walhovd, 2010).  Thus, aggressive and 
early interventions are required to conserve cognitive 
performance into later life and preserve the brain in a more 
youthful functional and physical state (Fjell and Walhovd, 
2010). 
 
Medical conditions 
 
Traumatic Brain Injuries 
 
It has been reported by the Australian Institute of Health and 
Welfare (Rutland-Brown et al., 2006) that in 2005 107 
Australian in every 100,000 people experienced long-term loss 
of function including cognitive impairments as a result of brain 
injuries (Arciniegas et al., 2002; Rutland-Brown et al., 
2006). At all levels of severity of TBI, the disturbances of 
memory, attention and executive functioning are considered to 
be the most common neurocognitive consequences (Arciniegas 
et al., 2002). Disturbances in memory and attention, the 
relatively basic cognitive functions, are specifically 
problematic, because they may result in, or exacerbate, 
additional disturbances in communication, executive function, 
and other complex cognitive functions (Arciniegas et al., 
2002). Thus, TBI is considered to be the leading cause of 
disability and death in industrialized countries in people less 
than 45 years of age (Arciniegas et al., 2002). 
 
Dementia 
 
Dementias are degenerative, progressive, irreversible disorders 
that gradually decrease an individual's ability to function in 
daily occupational and social activities (Dementia, 2011).  
Individuals may experience impairment in memory, language 
skills, orientation, judgment and/or executive functioning. 
People with dementia are not able to restore their previous 
level of functioning, although some of their symptoms may be 
managed through treatment. (Dementia, 2011) There are many 
types of dementia such as Lewy body dementia or vascular 
dementia. However, Alzheimer's disease is the most common 
form of dementia accounting for nearly 60-80% of all 
dementias. (Wong et al.,2013) Alzheimer’s disease cannot yet 
be prevented or cured, and the evidence it can be slowed in its 
progression is equivocal (Wong et al., 2013).  
 
Modifiable causes (reversible) of cognitive impairment 
 
Medical condition 
 
There are many medical conditions which have the potential to 
cause cognitive impairment including delirium, depression, 
low HDL levels, hypertension, diabetes and insulin resistance 
(Table II) (Bellew et al., 2004; Biessels et al., 2006; Centeno, 
et al., 2004; Panza et al., 2010; Ward et al., 2010). 
 
Medications 
 
Psychoactive Drugs 
 
One of the commonest causes of medication-induced cognitive 
impairment is psychoactive drugs (Francis et al., 1990;  Larson 
et al., 1987; Marcantonio et al., 1994). The toxicity of these 
medications is dose-related as well as to the vulnerability of 
each patient. Delirium and dementia severity has been linked 
to benzodiazepines. One study showed that 14% of 50 
delirious patients had benzodiazepine toxicity (Francis et al., 
1990). Delirium has been associated with longer-acting 
benzodiazepines, such as diazepam, and high dose treatment 
(more than 5 mg/day or equivalent) (Starr and Whalley, 1994). 
Also, long-acting benzodiazepines are the commonest 
medications reported to cause dementia (Starr & Whalley, 
1994). Moreover, a common cause of delirium in hospital 
patients is the abrupt withdrawal of short-acting 
benzodiazepines (Francis et al., 1990). Barbiturates have the 
potential to cause chronic cognitive impairment mimicking 
Alzheimer’s disease (Moore and O'Keeffe, 1999). Other 
psychoactive medications which contribute to cognitive 
impairment include: opioid analgesics, antipsychotics, 
antiparkinsonian drugs, antidepressants and anticonvulsants 
(Moore and O'Keeffe, 1999). 
 
Non-psychoactive Drugs 
 
Non-psychoactive medication-induced cognitive impairment is 
easily missed due to its idiosyncratic nature (Moore & 
O'Keeffe, 1999). Histamine-2 (H2) receptor antagonists have 
been linked with acute CNS toxicity including delirium (Cantu 
and Korek, 1991). A literature overview concluded that there 
was no difference between different H2 antagonists in relation 
to their CNS toxicity although cimetidine has been mentioned 
in many reports (Cantu and Korek, 1991). Although rare in 
outpatients, it has been shown that 1-2% of all hospital patients 
(Kowalsky et al., 1989) and 15-80% of intensive care patients 
(Schentag et al., 1979) suffered H2 antagonists-induced CNS 
toxicity. Additionally, proton pump inhibitors such as 
omeprazole have the potential to cause delirium. Idiosyncratic 
cognitive impairment has been seen among patients using 
calcium channel blockers (Maxwell et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table I. Number of articles per search term 
 
Search term: Cognitive impairment 
Data bases Articles found 
with first search 
Articles excluded 
before being reviewed 
due to publication date 
(<1975) and language 
(other than English).  
Articles 
included 
For the first 
review 
Articles excluded second 
round due to subjects’ 
age (<65 years) and the 
unavailability of full text  
Final number of 
articles included 
and cited in the 
thesis to develop 
the research concept 
Final number of 
articles included 
and cited in this 
literature review 
article 
Medline 46,675 2,807 43,868 38,856 5 3 
PubMed  117,982 10,096 107,886 77,875 10 9 
Google 
Scholar  
2,210,000 770,000 1,440,000 1423000 1 0 
Website 8,340,000 10,000 8,330,000 4,280,000 5 4 
Search term: Cognitive impairment AND causes 
Data bases Articles found 
with first search 
Articles excluded 
before being reviewed 
due to publication date 
(<1975) and language 
(other than English).  
Articles 
included 
For the first 
review 
Articles excluded second 
round due to subjects’ 
age (<65 years) and the 
unavailability of full text  
Final number of 
articles included 
and cited in the 
thesis to develop 
the research concept 
Final number of 
articles included 
and cited in this 
literature review 
article 
Medline 4,377 332 4,045 3771 7 4 
PubMed  59,367 5,290 54,077 38,737 13 9 
Google 
Scholar  
1,440,000 1,422,500 17,500 500 12 4 
Website 11,400,000 4250,000 7,150,000 2,870,000 0 0 
Search term: Cognitive impairment AND modifiable causes 
Data bases Articles found 
with first search 
Articles excluded 
before being reviewed 
due to publication date 
(<1975) and language 
(other than English).  
Articles 
included 
For the first 
review 
Articles excluded second 
round due to subjects’ 
age (<65 years) and the 
unavailability of full text  
Final number of 
articles included 
and cited in the 
thesis to develop 
the research concept 
Final number of 
articles included 
and cited in this 
literature review 
article 
Medline 1,653 56 1,597 1,443 1 1 
PubMed  267 8 259 134 10 8 
Google 
Scholar  
32,600 16,500 16,100 100 2 1 
Website 141,000 79,700 61,300 600 1 1 
Search term: Cognitive impairment AND non-modifiable causes 
Data bases Articles found 
with first search 
Articles excluded 
before being reviewed 
due to publication date 
(<1975) and language 
(other than English).  
Articles 
included 
For the first 
review 
Articles excluded second 
round due to subjects’ 
age (<65 years) and the 
unavailability of full text  
Final number of 
articles included 
and cited in the 
thesis to develop 
the research concept 
Final number of 
articles included 
and cited in this 
literature review 
article 
Medline 3,673 143 3,530 3,201 2 2 
PubMed  7 0 7 3 1 0 
Google 
Scholar  
3,390 80 3,310 1120 1 1 
Website 139,000 94900 44,100 17,900 0 0 
Search term: Cognitive impairment AND medications and pharmacist role AND cognitive impairment 
Data bases Articles found 
with first search 
Articles excluded 
before being reviewed 
due to publication date 
(<1975) and language 
(other than English).  
Articles 
included 
For the first 
review 
Articles excluded second 
round due to subjects’ 
age (<65 years) and the 
unavailability of full text  
Final number of 
articles included 
and cited in the 
thesis to develop 
the research concept 
Final number of 
articles included 
and cited in this 
literature review 
article 
Medline 4 0 4 3 1 0 
PubMed  9 1 8 6 2 0 
Google 
Scholar  
25,600 9,100 16,500 300 4 3 
Website 3,190,000 2,482,000 708,000 693,500 0 0 
Total of all searches 78 50 
 
Table II: Summery of modifiable medical conditions which have the potential to cause cognitive impairment 
 
Medical condition 
Delirium Delirium is a  transient confusion state of acute sudden onset & fluctuating course, with altered level of consciousness and 
abnormal attention, and/or thinking disturbances such as disordered perception, cognition and/or behaviour (Centeno et al., 
2004).  These symptoms develop over a short time period and tend to change throughout a 24-hour period , it has been 
demonstrated that reduction of acetylcholine as well as changes in serotonin, γ-aminobutyric acid, histamine, and 
noradrenaline have the potential to develop delirium. Delirium is a serious problem which is associated with greater 
mortality (rates from 10% to 65%) (Inouye, 1994), long hospital stays, high healthcare costs, high rates of 
institutionalization as well as less functional independence (Wei, Fearing, Sternberg, & Inouye, 2008). It has been shown 
that delirium increases hospital costs by at least $2,500 per patient (Wei et al., 2008). There are many causes that contribute 
to delirium including: infections with or without sepsis, fluid or electrolyte abnormalities, hypoglycaemia, hypoxemia, acute 
drug withdrawal from benzodiazepines, ethanol or barbiturates and drug intoxications. Additionally chronic use of 
benzodiazepine considered as one of the most common causes of delirium (Johnson, Sims, & Gottlieb, 1994).  
continue………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other non-psychoactive medications that result in cognitive 
impairment include: corticosteroids, non-steroidal anti-
inflammatory drugs and some antibiotics (Moore and 
O'Keeffe, 1999). A concurrent biochemical imbalance may be 
a factor in the higher incidence in hospitalised patients.  
 
Anticholinergic Drugs 
 
Due to the role of the cortical cholinergic system in memory 
function and attention processes (Sarter and Bruno, 1997), the 
central side effects of medications with anticholinergic 
properties are associated with attention deficit, confusion and 
impaired concentration and memory. Moreover, medications 
which block muscarinic cholinergic receptors have been 
conclusively demonstrated in many pharmacological studies to 
impair working memory for some stimuli and the encoding of 
new memories (Hasselmo, 2006). Many studies have 
demonstrated short term or cross-sectional links between 
functional or cognitive impairment and the use of medications 
which exhibit anticholinergic properties (Ball et al., 2013). A 
study conducted among the elderly found that delirium was 
linked with higher serum anticholinergic activity (Hasselmo, 
2006). According to a study conducted among a eugeria 
population of 372 sample size, the continued use of 
anticholinergic medications was associated with greater risk of 
having mild cognitive impairment and poorer performance on 
language tasks, attention, visuospatial construction, narrative 
recall, delayed non-verbal memory and reaction time (Ancelin 
et al., 2006). Also, the PAQUID population study (n=1780) 
showed a significant association between the use of 
anticholinergic medications and the poorer performance on the 
mini-mental state examination (MMSE), visual memory and 
verbal fluency (Lechevallier-Michel et al., 2005). In addition, 
the BRAiNS study with 3075 participants showed that the 
baseline use of anticholinergics has led to accelerated decline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
over six years on psychomotor speed, executive functioning 
and attention (Bottiggi et al., 2006). The Health Aging and 
Body Composition study, which was based on a sample of 
3075 people, reported that on the digit symbol substitution test, 
the use of medications with anticholinergic properties was 
associated with poorer performance (Hilmer et al., 2007). It 
has been reported in the elderly volunteers amongst 
psychogeriatric inpatients with moderate to severe dementia 
(n=26) (Chew et al., 2005) and a community dwelling cohort 
(n=201) (Mulsant et al., 2003) that the serum anticholinergic 
levels are associated with slowing in simple response time, and 
poorer MMSE scores. Several reports showed serum 
anticholinergic activity interacts with white matter hyper-
intensity volume. A study found that on implicit learning and 
number comparison, participants with both greater 
anticholinergic levels and higher hyper-intensity volumes were 
performing most poorly among participants (Nebes et al., 
2005). This suggests that medications with anticholinergic 
properties have the potential to exacerbate the cognitive 
decline due to the morphological changes in the brain (Nebes 
et al., 2005). A recent cohort community-dwelling study of 
544 older men who suffered hypertension, demonstrated that 
cumulative anticholinergic exposure can lead to poor 
performance on verbal memory over 2 years (Carriere et al., 
2009). Thus, several cross sectional studies conducted in the 
elderly have demonstrated a link between anticholinergic 
medication and psychomotor speed, global cognitive 
functioning, implicit learning, cognitive functioning and 
declarative and visual memory (Carriere et al., 2009). 
Moreover, cognitive impairment has been identified as central 
to abnormalities in different medical conditions such as 
schizophrenia and dementia.  The use of medications with 
anticholinergic properties has the potential to exacerbate pre-
existing impairment. Dementia is one of the most common 
medical conditions in the elderly population (Ball et al., 2013) 
Depression Depression has a close relationship with cognitive dysfunction. It has been shown in many studies that depression has the 
potential to deteriorate cognitive dysfunction, but individuals with poor cognitive health are predisposed to depression too 
(Panza et al., 2010). Furthermore, a study which assessed the relationship between depression and  age-related cognitive 
function,  showed that more than 50% of depressed individuals scored less than 10% of the control subjects (those non-
depressed and of same age and sex group), based on various cognitive tests which they completed (Butters et al., 2004). It 
has been concluded that depression which occurs later in life is associated with impaired information processing that affects 
cognition as a whole (Butters et al., 2004).  “Depression-associated reversible dementia,” has been defined as a cognitive 
impairment which is associated with depression and resolves upon treatment of depression (Alexopoulos, Meyers, Young, 
Mattis, & Kakuma, 1993). However, it has been shown that over approximately three years individuals with depression-
related dementia were roughly five times more likely to establish  true dementia (Alexopoulos et al., 1993).  
HDL levels Fluctuated HDL levels have been linked with cognitive function. Individuals with low HDL levels, potentially, at greater 
risk for future cognitive impairment than those with high HDL levels (Ward et al., 2010). One study of 183 subjects (mean 
age was 58 years) showed that the volume brain grey matter were positively associated with HDL levels based on MRI 
images (Ward et al., 2010). Moreover, individuals with higher HDL levels also scored considerably higher than those with 
lower HDL on a visuo-spatial memory test (Ward et al., 2010).  
Hypertension Chronic high blood pressure has the potential to damage cerebro-capillaries as they are small and delicate. This damage 
associates with cognitive impairment and neurodegenerative diseases development. A case-control study of more than 700 
patients showed the strong association between rate of cognitive impairment and blood pressure over a period of six months 
for individuals ≤ 65 years (Bellew et al., 2004). Another observational study of ≥ 1800 subjects showed that people taking 
one antihypertensive medication were at lower risk for dementia development  over a period of three years and less likely to 
have dementia at the time of the study. Moreover, individuals who weren’t on any antihypertensive medications and did 
suffer dementia at baseline exhibited a two-fold faster rate of cognitive impairment than individuals with dementia whose 
hypertension is controlled by medication. Furthermore, a study which followed 717 subjects for 38 years showed that 
individuals with normal systolic blood pressure perform better than those with systolic blood pressure of ≥140 mmHgbased 
on a composite measure of memory and verbal learning (Swan, Carmelli, & Larue, 1998).  
Diabetes and 
Insulin Resistance 
 
Small changes in the metabolism of glucose can impact cognitive function due to the brain’s high metabolic demand for 
energy. Diabetes (hyperglycaemia) has been associated  with increased incidence of all types of dementia (Biessels et al., 
2006). A study of 23 patients (diabetic or pre-diabetic) and 6 subjects without diabetes with a mean age of 74 years showed 
that during the memorization task both groups show different patterns of brain activity and glucose usage (Baker et al., 
2011). Upon the recall attempt, subjects with impaired glucose metabolism remembered fewer words compare with control 
subjects. Moreover, diabetic/pre-diabetic patients’ FDG-PET scans resembled Alzheimer’s patients’ brain scans (Baker et 
al., 2011). Another study showed that diabetes has harmful effects on the integrity of neurons (van Elderen et al., 2010). 
The progression of brain atrophy was accelerated with considerable consequences in cognition among type-2 diabetic 
elderly patients compared to individuals without type-2 diabetes (van Elderen et al., 2010). Moreover, a different study 
showed that overall cognitive decline was associated with higher insulin secretion and greater fasting insulin in older 
individuals (Okereke et al., 2010). 
 
The number of Australians who suffered dementia in 2011 was 
298,000 (Ball et al., 2013). By the year 2050 number of 
dementia cases will approach 900,000 (Ball et al., 2013; Landi 
et al., 2007). Most of those diagnosed with dementia are 
expected to suffer Alzheimer’s disease(Fortin et al., 2011). 
The earliest and most frequent symptom of Alzheimer’s 
disease is memory impairment, which can trigger further 
investigations by health professionals of the potential causes. 
(Fortin et al., 2011) During the early stages of Alzheimer’s 
disease the episodic memory is impaired.(Fortin et al., 2011) 
Thus, the partial restoration of the brain’s acetylcholine levels 
is the main goal of Alzheimer’s disease treatment (Fortin et al., 
2011). However, the elderly are often prescribed medications 
with anticholinergic properties although they often complain of 
memory loss and are at risk of Alzheimer’s disease (Fortin et 
al., 2011). Many medications are not recognised to have 
anticholinergic properties (Fortin et al., 2011). It has been 
estimated that about 600 medications have unwanted 
anticholinergic properties (Tune, 2000). There is potential that 
those patients receiving medications with anticholinergic side 
effects may be misdiagnosed with irreversible cognitive 
impairment or their pre-existing memory impairment become 
worse (Fortin et al., 2011). Additionally, literature has shown 
that treatments combining multiple drugs with modest 
anticholinergic activity have the potential to increase cognitive 
impairment in an elderly population with dementia (Thienhaus 
et al., 1990).  
 
DISCUSSION 
 
Chronic use of medications with anticholinergic side effects 
may promote the development of delirium in people who are 
diagnosed with one or more chronic diseases who are frail or 
aged. The severity of delirium may increase with certain 
medications, which normally may not cause the same intensity 
of effect when administered to other less vulnerable or younger 
patients. Comprehensive list was collated by fox et al. 2011 
(Fox et al., 2011) such as tricyclic antidepressant (TCA), 
oxybutynin and frusemide (Fox et al., 2011). Hypothetically, 
to establish a possible relationship between medication and 
cognitive impairment, the medication administration must 
precede the onset of cognitive impairment or worsening within 
a period of time, often hours to days based on the medication 
half-life (steady state or area under the curve as applicable), 
and the cessation of the suspected drug resulting in the 
improvement or restoration of the patient’s cognitive function 
(this is the hypothesis of an ongoing study conducted by 
corresponding author). The literature also shows that 
medications are among the most reported causes of delirium in 
the elderly patients presenting to emergency departments 
(Moore and O'Keeffe, 1999). More than one study showed that 
medications with anticholinergic properties increase the 
accumulative risk of cognitive impairment including delirium 
and counted for 11-30%  of elderly hospital patients (Fox et 
al., 2011; George et al., 1997; O'Keeffe and Lavan, 1999). 
Additionally, it has been shown that the relative odds ratio of 
medication-induced cognitive impairment was 1.0 when the 
patient used 0-1 medication and was elevated to 9.3 when the 
patient used 4-5 medications (Moore and O'Keeffe, 1999). 
However, this is not always the case. Using medications to 
treat different medical conditions has been shown to 
potentially reduce cognitive impairment. Individuals, who had 
untreated hypertension and dementia at baseline, exhibited a 
two-fold greater rate of cognitive impairment than individuals 
with dementia whose hypertension is controlled by medication. 
It has been shown that overall cognitive decline was associated 
with higher insulin secretion and greater fasting insulin in 
older individuals (Okereke et al., 2010) and depression has the 
potential to worsen cognitive dysfunction (Panza et al., 2010). 
Thus, although some cognitive impairment caused by 
medications cannot be reversed due to the absence of 
alternatives. This inability to removing this anticholinergic 
burden is considered to be one of the leading cause of 
disability in industrialized countries This bring the question of 
the possibility, when alternative can be found, to reverse some 
or the entire of the diagnosed cognitive impairment  through 
reviewing patients’ medication regimen by a pharmacist 
(Wong et al., 2013). 
 
Conclusion  
 
While pharmacists can contribute to the identification of 
cognitive impairment caused by medications, more research is 
required to improve pharmacy services including the 
management of medications with anticholinergic burden. The 
review identified the gap that pharmacists may have the 
capacity to fill through protocols used medication review.  
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